Pharmaceuticals & Biotech.
Pharmaceuticals & Biotech.
SECTOR | 24 Aug 2023
buy
by ICICI Securities Limited
ICICI Securities Limited
Windfall from the ongoing drug shortages and traction in gRevlimid sales in the US drove 16% / 45% / 41% YoY increase in revenue / EBITDA / PAT in Q1FY24 for the pharma companies under our coverage. Gross and EBITDA margins rose 300bps / 440bps YoY to 65.3% / 23.8% on an aggregate basis.
 
More from Pharmaceuticals & Biotech.
Recommended
Market trades higher, Garden Reach signs an MoU with the PWD, Nagaland
Trendlyne Marketwatch | 20 Mar 2025, 11:21AM
Five stocks to buy from analysts this week - March 18, 2025
The Baseline | 18 Mar 2025, 05:17PM
Volume-led growth, price stabilization and new US launches boost Indian pharma
| 25 Mar 2024